title: Reciprocal roles of angiotensin II and Angiotensin II Receptors Blockade (ARB) in regulating Cbfa1/RANKL via cAMP signaling pathway: possible mechanism for hypertension-related osteoporosis and antagonistic effect of ARB on hypertension-related osteoporosis.
abstract: Hypertension is a risk factor for osteoporosis. Animal and epidemiological studies demonstrate that high blood pressure is associated with increased calcium loss, elevated parathyroid hormone, and increased calcium movement from bone. However, the mechanism responsible for hypertension-related osteoporosis remains elusive. Recent epidemiological studies indicate the benefits of Angiotensin II Receptors Blockade (ARB) on decreasing fracture risks. Since receptors for angiotensin II, the targets of ARB, are expressed in both osteoblasts and osteoclasts, we postulated that angiotensin II plays an important role in hypertension-related osteoporosis. Cbfa1 and RANKL, the important factors for maintaining bone homeostasis and key mediators in controlling osteoblast and osteoclast differentiation, are both regulated by cAMP-dependent signaling. Angiotensin II along with factors such as LDL, HDL, NO and homocysteine that are commonly altered both in hypertension and osteoporosis, can down-regulate the expression of Cbfa1 but up-regulate RANKL expression via the cAMP signaling pathway. We thus hypothesized that, by altering the ratio of Cbfa1/RANKL expression via the cAMP-dependent pathway, angiotensin II differently regulates osteoblast and osteoclast differentiation leading to enhanced bone resorption and reduced bone formation. Since ARB can antagonize the adverse effect of angiotensin II on bone by lowering cAMP levels and modifying other downstream targets, including LDL, HDL, NO and Cbfa1/RANKL, we propose the hypothesis that the antagonistic effects of ARB may also be exerted via cAMP signaling pathway.
authors.affiliation: State Key Laboratory of Oral Diseases, Sichuan University, Chengdu 610041, China; E-Mails: gsunrise@yahoo.cn (X.-X.G.); zhouyizyzyzy@163.com (Y.Z.).
authors.forename: Xiao-Xu
authors.initials: XX
authors.lastname: Guan
authors.forename: Yi
authors.initials: Y
authors.lastname: Zhou
authors.forename: Ji-Yao
authors.initials: JY
authors.lastname: Li
mesh_terms: D000804:Angiotensin II / Q000494:pharmacology*; D057912:Angiotensin II Type 2 Receptor Blockers / Q000494:pharmacology*; D050659:Core Binding Factor Alpha 1 Subunit / Q000378:metabolism*; D000242:Cyclic AMP / Q000378:metabolism*; D061307:Human Umbilical Vein Endothelial Cells; D006801:Humans; D006973:Hypertension / Q000150:complications; D008075:Lipoproteins, HDL / Q000097:blood; D008077:Lipoproteins, LDL / Q000097:blood; D009569:Nitric Oxide / Q000097:blood; D010024:Osteoporosis / Q000209:etiology; D053245:RANK Ligand / Q000378:metabolism*; D044139:Receptor, Angiotensin, Type 2 / Q000737:chemistry / Q000378:metabolism; D015398:Signal Transduction / Q000187:drug effects*
chemical_list: D057912:Angiotensin II Type 2 Receptor Blockers; D050659:Core Binding Factor Alpha 1 Subunit; D008075:Lipoproteins, HDL; D008077:Lipoproteins, LDL; D053245:RANK Ligand; D044139:Receptor, Angiotensin, Type 2; D000804:Angiotensin II; D009569:Nitric Oxide; D000242:Cyclic AMP